SUMMARY Polyethylene glycol (PEG) 4000 is one of numerous substances used as non-absorbable markers to correct for variable faecal output when assessing daily faecal losses of nutrients. The introduction of enteric coated micro-encapsulated pancreatic enzyme (EMPE) preparations has greatly improved the control of fat malabsorption in cystic fibrosis and chronic pancreatitis patients. Unfortunately, these enzyme preparations contain significant quantities of PEG 4000 or polyvinyl pyrolidine (PVP) Radio-opaque pellets were prepared by cutting 1.0-1-5 mm lengths of Portex 2-0 mm internal diameter radio-opaque tubing; these were extracted overnight with toluene to remove the plasticiser and, after drying, were packaged in gelatin capsules, each of which contained eight pellets. For seven days 17 CF patients received 500 mg PEG (Sandoz Products Ltd, London) and eight ROP three times daily, and 11 received only eight ROP three times per day. Normal diet and medication were continued throughout the seven days. During the last 48 hours all stools were collected in separate strong polyethylene bags, which fitted directly on to a commode.Stools were frozen and then x-rayed. Radioopaque pellets were easily distinguished on x-ray films and were counted. The pooled two day collections were then homogenised and analysis was performed for PEG by the method of Malawer6 and for fat by the method of van de Kamer et al.7 Daily faecal fat output was calculated using each marker.